Page 72 - TD-4-2

Tumor Discovery Glioblastoma treating fields system

and future directions. Br J Cancer. 2021;124(4):697-709. fields (TTFields): Investigations on the mechanism of
action by electromagnetic exposure of cells in telophase/
doi: 10.1038/s41416-020-01136-5
cytokinesis. Sci Rep. 2019;9(1):7362.
12. Stupp R, Taillibert S, Kanner A, et al. Maintenance
therapy with tumor-treating fields plus temozolomide doi: 10.1038/s41598-019-43621-9
vs temozolomide alone for glioblastoma: A randomized 23. Li X, Yang F, Rubinsky B. A theoretical study on the
clinical trial. JAMA. 2015;314(23):2535-2543. biophysical mechanisms by which tumor treating fields
affect tumor cells during mitosis. IEEE Trans Biomed Eng.
doi: 10.1001/jama.2015.16669
2020;67(9):2594-2602.
13. Guo X, Yang X, Wu J, et al. Tumor-treating fields in
glioblastomas: Past, present, and future. Cancers (Basel). doi: 10.1109/TBME.2020.2965883
2022;14(15):3669. 24. Farmani A, Mahdavinezhad F, Scagnolari C, et al. An
overview on tumor treating fields (TTFields) technology
doi: 10.3390/cancers14153669
as a new potential subsidiary biophysical treatment for
14. Moser J, Salvador E, Deniz K, et al. The mechanisms of action COVID-19. Drug Deliv Transl Res. 2022;12(7):1605-1615.
of tumor treating fields. Cancer Res. 2022;82(20):3650-3658.
doi: 10.1007/s13346-021-01067-5
doi: 10.1158/0008-5472.Can-22-0887
25. Carrieri F, Smack C, Siddiqui I, et al. Tumor treating fields:
15. Voloshin T, Schneiderman R, Volodin A, et al. Tumor At the crossroads between physics and biology for cancer
treating fields (TTFields) hinder cancer cell motility through treatment. Front Oncol. 2020;10:575992.
regulation of microtubule and acting dynamics. Cancers doi: 10.3389/fonc.2020.575992
(Basel). 2020;12(10):3016.
26. Xiang X, Liu H, Tao X, et al. Glioblastoma behavior study
doi: 10.3390/cancers12103016
under different frequency electromagnetic field. iScience.
16. Chen W, Wang Y, Zhao B, et al. Optimal therapies for 2023;26(12):108575.
recurrent glioblastoma: A Bayesian network meta-analysis.
Front Oncol. 2021;11:641878. doi: 10.1016/j.isci.2023.108575
27. Tewatia K, Sharma A, Sharma M, et al. Factors affecting
doi: 10.3389/fonc.2021.641878
morphological and electrical properties of Barium Titanate:
17. Taphoorn M, Dirven L, Kanner A, et al. Influence of A brief review. Mater Today Proc. 2021;44:4548-4556.
treatment with tumor-treating fields on health-related doi: 10.1016/j.matpr.2020.10.813
quality of life of patients with newly diagnosed glioblastoma:
A secondary analysis of a randomized clinical trial. JAMA 28. Liu W, Kong F, Liang Y, et al. Strategy to achieve both
Oncol. 2018;4(4):495-504. enhanced dielectric tunability and reduced dielectric loss
in the barium zirconium titanate ceramics. Ceram Int.
doi: 10.1001/jamaoncol.2017.5082
2024;50(18):31759-31766.
18. Fabian D, Guillermo M, Alnahhas I, et al. Treatment of doi: 10.1016/j.ceramint.2024.05.354
glioblastoma (GBM) with the addition of tumor-treating
fields (TTF): A review. Cancers. 2019;11(2), 174. 29. Sumona H, Sultan M, Urmi S, et al. Investigation of
structural, electrical and optical properties of lanthanum
doi: 10.3390/cancers11020174
and zirconium doped barium titanate ceramics. Mater Sci
19. Mun E, Babiker H, Weinberg U, et al. Tumor-treating fields: Eng B. 2023;298:116844.
A fourth modality in cancer treatment. Clin Cancer Res. doi: 10.1016/j.mseb.2023.116844
2018;24(2):266-275.
30. Barsheshet Y, Voloshin T, Brant B, et al. Tumor treating fields
doi: 10.1158/1078-0432.CCR-17-1117
(TTFields) concomitant with immune checkpoint inhibitors
20. Anadkat M, Lacouture M, Friedman A, et al. Expert are therapeutically effective in non-small cell lung cancer
guidance on prophylaxis and treatment of dermatologic (NSCLC) in vivo model. Int J Mol Sci. 2022;23(22):14073.
adverse events with Tumor Treating Fields (TTFields) doi: 10.3390/ijms232214073
therapy in the thoracic region. Front Oncol. 2022;12:975473.
31. Pless M, Droege C, von Moos R, et al. A phase I/II trial of
doi: 10.3389/fonc.2022.975473
tumor treating fields (TTFields) therapy in combination
21. Pan J, Eskandar T, Ahmed Z, et al. Biophysical and biological with pemetrexed for advanced non-small cell lung cancer.
mechanisms of tumor treating fields in glioblastoma. Lung Cancer. 2013;81(3):445-450.
J Cancer Sci Clin Ther. 2024;8(3):265-270.
doi: 10.1016/j.lungcan.2013.06.025
doi: 10.26502/jcsct.5079249
32. Giladi M, Schneiderman R, Porat Y, et al. Mitotic disruption
22. Berkelmann L, Bader A, Meshksar S, et al. Tumour-treating and reduced clonogenicity of pancreatic cancer cells

Volume 4 Issue 2 (2025) 64 doi: 10.36922/td.7171